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Abstract
Background: Taking folic acid supplements before pregnancy to reduce the risk of a neural tube defect (NTD) is especially
important in countries without universal folic acid fortification. The extent of folic acid supplementation among women
who had antenatal screening for Down’s syndrome and NTDs at the Wolfson Institute of Preventive Medicine, London
between 1999 and 2012 was assessed.
Methods and Findings: 466,860 women screened provided details on folic acid supplementation. The proportion of
women who took folic acid supplements before pregnancy was determined according to year and characteristics of the
women. The proportion of women taking folic acid supplements before pregnancy declined from 35% (95% CI 34%–35%) in
1999–2001 to 31% (30%–31%) in 2011–2012. 6% (5%–6%) of women aged under 20 took folic acid supplements before
pregnancy compared with 40% of women aged between 35 and 39. Non-Caucasian women were less likely to take folic acid
supplements before pregnancy than Caucasian women; Afro-Caribbean 17% (16%–17%), Oriental 25% (24%–25%) and
South Asian 20% (20%–21%) compared with 35% (35%–35%) for Caucasian women. 51% (48%–55%) of women who
previously had an NTD pregnancy took folic acid supplements before the current pregnancy.
Conclusions: The policy of folic acid supplementation is failing and has led to health inequalities. This study demonstrates
the need to fortify flour and other cereal grain with folic acid in all countries of the world.
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Introduction
In 1991 the results of the Medical Research Council Vitamin
Study were published. This randomised controlled trial showed
that taking folic acid before conception reduced the risk of a neural
tube defect (NTD) pregnancy by an estimated 72% [1]. A high
enough daily intake of folate to provide such a reduction in risk
cannot easily be obtained by dietary changes so supplementation is
necessary, particularly in countries where folic acid fortification
has not been implemented. Mandatory fortification has been
introduced in over 70 countries including the US, Canada and
Australia [2], but despite evidence that such fortification is
effective [3–5], over 120 countries have not introduced mandatory
folic acid fortification, including all countries in the European
Union, so women of child bearing age need to take folic acid
supplements before pregnancy to reduce their risk of an NTD
pregnancy. In 1998, 6 years after the UK Department of Health
recommendation on the intake of folic acid before pregnancy [6]
the proportion of women from one hospital screened at the
Wolfson Institute of Preventive Medicine, London who took folic
acid supplements before pregnancy was reported to be 42% (523/
1238) [7]. We here assess the extent of folic acid supplementation
using data from almost half a million women screened at the
Wolfson Institute between 1999 and 2012.
Methods
Ethics Statement
The results in the paper arose out of an audit of our screening
service for which no explicit consent was sought but women
screened were informed that data arising from the screening
programme might be used to make improvements to the services
provided. All the data were anonymous and no enquiries or
procedures were performed other than those that formed part of
the routine service so ethical approval was not required.
In 1998 the antenatal Down’s syndrome and NTD screening
service at the Wolfson Institute of Preventive Medicine, London
introduced a question on screening request forms asking whether
women had (i) started taking folic acid supplements before
pregnancy, (ii) started once pregnancy was confirmed or (iii) not
taken folic acid supplements. Between January 1999 and
December 2012 520,570 pregnant women were routinely screened
at the Wolfson Institute for Down’s syndrome using the late first
trimester (11–13 weeks’ gestation) Combined test (61%; median
gestational age 12 weeks, 5 days) or the early second trimester (15–
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20 weeks’ gestation) Quadruple test (39%; median gestational age
16 weeks, 3 days). Women screened with the Quadruple test were
also screened for NTDs using maternal serum alphafetoprotein,
collected as part of the Quadruple test, and a further 867 women
were screened for NTDs only. A total of 466,860 (90%; lower
proportion in earlier years as the new request forms were being
introduced) provided data on folic acid supplement status. The
proportion of women who started taking folic acid supplements
before pregnancy was determined for each calendar year. Data on
the following specified factors that are routinely collected as part of
the screening service were used to determine the independent
effects of each: previous NTD pregnancy (yes/no), previous
Down’s syndrome pregnancy (yes/no), ethnicity (Caucasian, Afro-
Caribbean, South Asian [Indian, Pakistani, Bangladeshi or Sri-
Lankan], Oriental [Chinese, Japanese or South East Asian] or
Other), insulin dependent diabetes mellitus (yes/no), in-vitro
fertilisation (IVF, yes/no), smoker (yes/no), maternal weight (five
10 kg categories) and maternal age (seven 5-year categories),
region of residence (categorised as strategic health authorities and
the Isle of Man), and time of screening (first or second trimester).
The relative use of taking folic acid supplements before pregnancy
versus not taking folic acid supplements before pregnancy was
calculated according to these factors and categories. Adjusted
relative use estimates were calculated using multivariate Poisson
regression with robust variances [8]. The average marginal effects
were calculated to estimate the adjusted percentages of women
taking folic acid before pregnancy i.e. the percentages independent
of the specified factors. All analyses were performed in Stata
version 12 (StatCorp, College Station, Texas).
Results
Figure 1 shows the strategic health authorities of England, and
the Isle of Man where women provided blood samples for
screening. Fifty-eight percent of women were from London, 27%
from the South East, 11% from the North West, with the
remainder from the East of England, Isle of Man and the South
West.
All factors were statistically significantly associated with taking
folic acid supplements before pregnancy (all p,0.001) and each
factor, adjusting for all other factors, remained statistically
significant (all p,0.001; see Table S1). Figure 2 shows that
between 1999–2001 and 2002–2004 the observed proportion of
women taking folic acid supplements before pregnancy reduced
from 35% (95% CI 34%–35%) to 31% (30%–31%) and in the
following ten years the proportion remained stable. The adjusted
percentage taking folic acid supplements before pregnancy
reduced in each period from 40% (39%–41%) in 1999–2001 to
28% (28%–28%) in 2011–2012.
Figure 3 shows that younger women were less likely to take folic
acid supplements before pregnancy than older women; 6% (5%–
6%) of women aged under 20 and 40% of women aged between
35 and 39. The adjusted percentage of women taking folic acid
supplements before pregnancy peaked at 38% (38%–38%) in
women aged 35–39 and was 31% (29%–33%) in women aged 45
or older.
Figure 4a shows that non-Caucasian women were less likely to
take folic acid supplements before pregnancy than Caucasian
women; 35% (35%–35%) of Caucasian women took folic acid
supplements before pregnancy compared with 17% (16%–17%) of
Afro-Caribbean women, 20% (20%–21%) of South Asian women,
25% (24%–25%) of Oriental women and 23% (22%–23%) of
women of other ethnic groups. Adjusted percentage estimates were
similar to the unadjusted values.
Figure 4b shows that 51% (48%–55%) of women with a
previous NTD affected pregnancy took folic acid supplements
before their current pregnancy compared with 30% (30%–30%) of
women without a previous NTD affected pregnancy (adjusted
figures similar).
Table S1 shows results for other factors and gives unadjusted
and adjusted relative use of folic acid supplements before
pregnancy, from which adjusted percentages were derived. These
results show that (i) women who had undergone IVF were most
likely to take folic acid supplements prior to pregnancy, but despite
being under close medical supervision 20% of them were not
doing so, (ii) women who had previously had a pregnancy affected
with Down’s syndrome were more likely to take folic acid
supplements before pregnancy than those who had not, but the
proportion was still only about half, (iii) insulin dependent diabetic
women were more likely to take folic acid supplements before
pregnancy than non-insulin dependent diabetic women, (iv)
smokers were less likely to take folic acid supplements before
pregnancy than non-smokers and (v) women who were screened in
the second trimester were less likely to take folic acid supplements
than women screened in the first trimester, possibly because a
greater proportion of women who had second trimester screening
had unplanned pregnancies that were confirmed later in gestation.
Discussion
This study has four main findings. Firstly, relatively few women
are taking folic acid supplements before pregnancy, with the
proportion declining over the study period, from 35% in 1991–
2001 to about 30% in 2011–2012. However, as women are having
children at older ages and more women are having IVF, and these
women were more likely to take folic acid supplements before
pregnancy, the extent of the year-specific downwards trend is
concealed. Perhaps more relevant is the observation that the
adjusted percentage of women taking folic acid supplements before
pregnancy declined from 40% in 1999–2001 to 28% in 2011–
2012. Secondly non-Caucasian women were about half as likely as
Caucasian women to take folic acid supplements before pregnan-
cy. This probably reflects socio-economic status, demonstrating an
example of health inequalities. Thirdly, whilst women who had
previously had an NTD pregnancy were more likely to take folic
acid supplements before pregnancy than women who had not,
only about half of them did. Further, 16 women had had two
previous NTD pregnancies; only five of them took folic acid
supplements before pregnancy. Fourthly, younger women were far
less likely to take folic acid supplements before pregnancy; women
younger than 20 were five times less likely to take folic acid
supplements before pregnancy than women aged 30 or over. This
may be partly due to more unplanned pregnancies and less
knowledge of the benefits of folic acid supplementation in younger
women. After adjustment the percentage of women aged 45 or
older taking folic acid supplements prior to pregnancy was 31%,
lower than the percentage of women aged 40–44 (36%) despite the
unadjusted percentages being the same (40%). The main
contributor to the lower adjusted percentage for women aged 45
or older compared with women aged 40–44 is the proportion of
women who had undergone IVF treatment (who were most likely
to take folic acid before pregnancy) in the 45 or older age group;
34% compared with 7% of women aged 40–44.
During the study period the proportion of women who started
taking folic acid supplements after pregnancy had been confirmed
increased from 45% to 62% (see Table S1). However, to prevent
NTDs folic acid supplements need to be taken before pregnancy;
there is little to no benefit of taking folic acid supplements after
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pregnancy has been confirmed as the neural tube (and any defect)
will have formed by around 8 weeks of pregnancy.
A strength of this study is the large sample size; almost half a
million pregnancies resulting in very narrow confidence intervals
of our estimates and even small differences are highly statistically
significant. The results show that the policy of folic acid
supplementation has failed. The policy exacerbates health
inequalities among ethnic minorities and younger women. Our
study is based on women from England and the Isle of Man, but
the results are similar to other countries; a review of 34 studies
conducted in 8 countries between 1992 and 2001 showed that
nowhere was the proportion of women taking folic acid
supplements before pregnancy greater than 50% and that overall
it was about 25% [9]. Our results show that over the past decade
the proportion has decreased in England. A weakness of this study
is that it is limited to women that had antenatal screening for
Down’s syndrome and neural tube defects. Uptake of screening in
England and Wales was 53% in 2007, increasing to 74% in 2011
[10].
The global number of spina bifida and anencephaly births has
been estimated at 300,000 to 400,000 per year [11]. In the 20
years since the publication of the MRC Vitamin Study 1,800,000
cases could have been prevented on the basis that fortification
alone would prevent one-third of cases. Among women that took
folic acid supplements this would be even higher. In contrast, an
estimated worldwide total of 10,000 people were disabled from
thalidomide [12] and this led to transformation of the drug
regulatory system. It is a public health tragedy that in spite of the
fortification initiative in many countries most have not introduced
mandatory folic acid fortification [2].
It is widely judged that folic acid fortification and supplemen-
tation is safe. Concerns over the possible increased risk of cancer
being associated with folic acid fortification are not justified
[13,14] and a large meta-analysis of placebo-controlled rando-
mised trials of folic acid (median daily dose 2.0 mg over an
average 5 years of follow-up) showed no increase in cancer
incidence in those taking folic acid [15]. Moreover there is
evidence that the generally recommended daily dose of folic acid
supplementation is too low at 0.4 mg; about 80% of all NTDs
could be prevented if it were 5 mg instead of about 50% with
0.4 mg [16]. Therefore fortification would offer additional
protection against NTDs for women taking the current recom-
mended daily dose.
Figure 1. Number of women who provided folic acid supplement status according to strategic health authority and the Isle of Man.
doi:10.1371/journal.pone.0089354.g001
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Figure 2. Observed and adjusted* percentage of women taking folic acid supplements before pregnancy according to year.
doi:10.1371/journal.pone.0089354.g002
Figure 3. Observed and adjusted* percentage of women taking folic acid supplements before pregnancy according to maternal
age.
doi:10.1371/journal.pone.0089354.g003
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The prevention of neural tube defects is a global problem. Our
results show that public health policy cannot rely on pre-
pregnancy folic acid supplementation alone. Improved education
in communities with particularly low rates of pre-pregnancy folic
Figure 4. Observed and adjusted* percentage of women taking folic acid supplements before pregnancy according to ethnicity (a)
and previous neural tube defect (NTD) pregnancy (b).
doi:10.1371/journal.pone.0089354.g004
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acid supplementation may increase the rates but for all women to
benefit countries that have not introduced folic acid fortification
should do so to avert a preventable serious birth defect responsible
for still births, severe physical disability and needless therapeutic
abortions.
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